{"nctId":"NCT04762719","briefTitle":"PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis","startDateStruct":{"date":"2021-05-10","type":"ACTUAL"},"conditions":["Diabetes","Gastroparesis With Diabetes Mellitus"],"count":12,"armGroups":[{"label":"Diabetic Gastroparesis Subjects","type":"EXPERIMENTAL","interventionNames":["Drug: PET/CT Scan with 11C-ER176","Diagnostic Test: Core biopsy of gastric muscle"]},{"label":"Diabetic without gastroparesis subjects","type":"EXPERIMENTAL","interventionNames":["Drug: PET/CT Scan with 11C-ER176"]},{"label":"Healthy Subjects","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: PET/CT Scan with 11C-ER176"]}],"interventions":[{"name":"PET/CT Scan with 11C-ER176","otherNames":[]},{"name":"Core biopsy of gastric muscle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age: 18 to 70 years of age.\n* Ability to provide informed consent.\n* Type I or II diabetes mellitus.\n* Gastroparesis defined by gastric retention of Tc-99m \\> 60 % at 2 hrs and/or \\> 10% at 4 hours on scintigraphy.\n* Average Gastroparesis Cardinal Symptom Index (GCSI) â‰¥ 3 indicating moderate-severe symptoms.\n\nExclusion Criteria:\n\n* Women who are pregnant or cannot stop breast feeding for 24 hours.\n* Using anti-coagulants, anti-inflammatory medications (NSAIDs, corticosteroids, etc.) or immunosuppressive therapies within the 4 weeks prior.\n* Opioid use within the last 4 weeks of gastric emptying scintigraphy.\n* Prior gastric surgery.\n* History of IBD, celiac disease, eosinophilic gastroenteritis, microscopic colitis.\n\nHealthy Subjects Exclusion criteria\n\n* no clinical history of diabetes or any GI symptoms\n* no inflammatory disorders of the GI tract\n* no use of anti-inflammatory or immunosuppressive therapies","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Uptake of 11C-ER 176 in the Stomach Muscle","description":"All patients will have a PET/CT with 11C-ER 176. On each PET image, volumes of interest areas will be drawn around the stomach and other organs that may show radiotracer accumulation. The uptake of radiotracer 11C-ER 176 in each area will be quantified and reported as maximum standardized uptake values (SUVmax)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"1.0"},{"groupId":"OG001","value":"8.4","spread":"4.1"},{"groupId":"OG002","value":"4.6","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"1.9"},{"groupId":"OG001","value":"13.1","spread":"8.3"},{"groupId":"OG002","value":"9.0","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"1.9"},{"groupId":"OG001","value":"13.0","spread":"9.2"},{"groupId":"OG002","value":"7.7","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"1.8"},{"groupId":"OG001","value":"9.5","spread":"6.8"},{"groupId":"OG002","value":"6.2","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Immune Cells With CD45 Expression","description":"An upper endoscopy procedure was done for diabetic gastroparesis patients and full thickness core tissue samples were taken in the stomach in areas that demonstrated 11C-ER 176 uptake in the PET scan as well as non-enhancing control areas. Cytometry by time of flight (CyTOF) mass spectrometry system was used to determine the proportions of immune cell types with CD45.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":["Sore throat","Uvular abrasion","Urinary Tract Infection"]}}}